Asenapine

Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0) . Asenapine can be used in the research of schizophrenia and bipolar disorder[1][2].

Product Specifications

CAS Number

[65576-45-6]

Product Name Alternative

Org 5222

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

5-HT Receptor; Adrenergic Receptor; Dopamine Receptor; Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Asenapine.html

Purity

99.62

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

ClC1=CC=C2OC3=CC=CC=C3[C@@](C4)([H])[C@](CN4C)([H])C2=C1

Molecular Formula

C17H16ClNO

Molecular Weight

285.77

Precautions

H315, H319, H335

References & Citations

[1]M Shahid, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23 (1) :65-73.|[2]Olivia Frånberg, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) . 2008 Feb;196 (3) :417-29.|[3]Ohyama M, et al. Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model. Acta Neuropsychiatr. 2016 Dec;28 (6) :327-336.|[4]Ene HM, et al. Effects of repeated asenapine in a battery of tests for anxiety-like behaviours in mice. Acta Neuropsychiatr. 2016 Apr;28 (2) :85-91. |[5]Stoner SC, Pace HA. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther. 2012 May;34 (5) :1023-40.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

D1 Receptor; D2 Receptor; D3 Receptor; D4 Receptor; H1 Receptor; H2 Receptor; mLAG-3; MUC2; MUC3; Prostaglandin D Synthase; α adrenergic receptor; α-1 microglobulin

Citation 01

Biomed Pharmacother. 2025 Jan:182:117756.|Biomed Pharmacother. 2025 Jan:182:117756.|Insect Biochem Mol Biol. 2025 May:180:104312.|Int J Biol Macromol. 2023 Aug 30:247:125703.